Samuel Murphy Ph.D

Samuel Murphy Ph.D General Information

Biography

Dr. Samuel Murphy serves as Chief Executive Officer & Board Member at Salubris Biotherapeutics. He served as Board Member at MedAlliance. His role encompasses the origination, evaluation, and execution of licensing transactions, strategic investments, and acquisitions outside of China. He leads the externally-facing efforts ongoing at Salubris Biotherapeutics to pivot toward an innovation-driven product portfolio and a global presence. Prior to joining Salubris Biotherapeutics, he worked for ten years in strategy consulting and transaction advisory services across several global firms including IMS (now IQVIA) and Simon-Kucher & Partners. His commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on pricing and market access. His transaction advisory work included licensing and acquisitions collectively exceeding $2B USD in value and he also supported early-stage financing for a number of emerging pharma/biotech companies. He completed his B.A. in Biochemistry, Ph.D. in Molecular Biology, and Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at the University of Pennsylvania, where he focused principally on gene therapy during his 13 years of bench research. He was also awarded a Presidential Management Fellowship in which he supported policy development around a $1B congressional initiative to build the national biodefense stockpile. He serves as a board member of GO Therapeutics, Viracta Therapeutics and a board observer at Mercator Medsystems.